• Industry News
  • Access and Reimbursement
  • Law & Malpractice
  • Coding & Documentation
  • Practice Management
  • Finance
  • Technology
  • Patient Engagement & Communications
  • Billing & Collections
  • Staffing & Salary

Will Screening for Nonadherence Damage Your Patients' Trust?


Should physicians routinely screen patients for medication adherence, like antihypertensive therapy? Could that damage the physician-patient relationship?

There is at present no good way to assess patient adherence to hypertensive drug therapy; a concern since the rates of reported poor adherence are anywhere from 3 percent to 65 percent. Now, researchers at the University of Leicester in England believe they have found a way.

They used a high-performance liquid chromatography-tandem mass spectrometry-based urine analysis to assess how well patients were taking their blood pressure meds, reported MedPage Today.

The assay is able to detect levels for the 40 most-commonly prescribed antihypertensive medications - however cost is a concern. While a single test is $50 U.S. dollars, the analyzer itself is $250,000.

Would you use such a diagnostic test, if it were available, to screen your hypertensive patients who have a poor response to drug therapy? Do you think the cost of the test would outweigh the benefits?

Could such a test harm the physician-patient relationship by indicating that you don't trust your patients to tell you the truth?

Share your thoughts in the comments box below.

Recent Videos
Ike Devji, JD and Anthony Williams discuss wealth management issues
Three experts discuss eating disorders
Ike Devji, JD and Anthony Williams discuss wealth management issues
Navaneeth Nair gives expert advice
Erin Jospe, MD, gives expert advice
Rachael Sauceman gives expert advice
Joe Nicholson, DO, gives expert advice
Dr. Janis Coffin, DO
Janis Coffin, DO
Dr. Janis Coffin, DO, FAAFP, FACMPE, PCMH CCE, gives expert advice
Related Content
© 2024 MJH Life Sciences

All rights reserved.